[Synthetic ACTH in theumatic diseases: (author's transl)].
44 patients with acute irritations of degenerative articular diseases and 66 patients with soft tissue rheumatism were treated with Synacthen Depot (tetracosactide hexacetate 1 mg/ml). During the first three days of treatment the patients received an average of 2 ampoulbs Synacthen Depot, then treatment was continued at 3-4 day intervals. In the degenerative joint disease group 86.4% and 89.4% in the group with soft tissue rheumatism became free of complaints or improved with the ACTH treatment. Most of the patients with degenerative joint diseases needed a 4 week treatment; 1/3 of the patients with soft tissue rheumatism were already free of complai
D000208:Acute Disease; D000324:Adrenocorticotropic Hormone / Q000031:analogs & derivatives*; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003366:Cosyntropin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D005356:Fibromyalgia / Q000188:drug therapy; D006621:Hip Joint; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy; D007719:Knee Joint; D008297:Male; D008875:Middle Aged; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013166:Spondylitis / Q000188:drug therapy
D003692:Delayed-Action Preparations; D003366:Cosyntropin; D000324:Adrenocorticotropic Hormone
Synthetisches ACTH beim rheumatischen Formenkreis